REGENXBIO, Inc. (RGNX)
8.07
-0.02
(-0.25%)
USD |
NASDAQ |
Oct 09, 16:00
8.075
0.00 (0.00%)
After-Hours: 20:00
REGENXBIO Free Cash Flow (Quarterly) : -63.00M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -63.00M |
| March 31, 2026 | -77.42M |
| December 31, 2025 | -52.80M |
| September 30, 2025 | -56.45M |
| June 30, 2025 | -49.73M |
| March 31, 2025 | 32.60M |
| December 31, 2024 | -32.70M |
| September 30, 2024 | -40.88M |
| June 30, 2024 | -45.97M |
| March 31, 2024 | -56.01M |
| December 31, 2023 | -41.89M |
| September 30, 2023 | -50.85M |
| June 30, 2023 | -49.90M |
| March 31, 2023 | -85.74M |
| December 31, 2022 | -44.84M |
| September 30, 2022 | -55.51M |
| June 30, 2022 | -70.99M |
| March 31, 2022 | -66.88M |
| December 31, 2021 | 311.62M |
| September 30, 2021 | -55.06M |
| June 30, 2021 | -49.71M |
| March 31, 2021 | -72.15M |
| December 31, 2020 | 26.58M |
| September 30, 2020 | -42.53M |
| Date | Value |
|---|---|
| June 30, 2020 | -24.77M |
| March 31, 2020 | -40.20M |
| December 31, 2019 | -26.54M |
| September 30, 2019 | -31.83M |
| June 30, 2019 | -29.30M |
| March 31, 2019 | -31.75M |
| December 31, 2018 | -9.029M |
| September 30, 2018 | -22.93M |
| June 30, 2018 | 67.54M |
| March 31, 2018 | 55.79M |
| December 31, 2017 | -15.93M |
| September 30, 2017 | -17.59M |
| June 30, 2017 | -11.23M |
| March 31, 2017 | -20.41M |
| December 31, 2016 | -24.86M |
| September 30, 2016 | -14.04M |
| June 30, 2016 | -9.505M |
| March 31, 2016 | -8.303M |
| December 31, 2015 | -4.571M |
| September 30, 2015 | -8.44M |
| June 30, 2015 | -8.211M |
| March 31, 2015 | -1.781M |
| March 31, 2014 | 1.213M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| AbbVie, Inc. | 3.114B |
| United Therapeutics Corp. | 202.20M |
| Ardelyx, Inc. | -6.412M |
| Biomea Fusion, Inc. | -10.03M |
| RenovoRx, Inc. | -2.938M |